| Abstract | Bone metastases is a serious complication of patients with tumor. It is associated with substantial morbidity, including bone pain, pathological fracture,neurological deficit and (or) hypercalcemia. Thus, the management of bone metastasis is a clinically significant issue. Bisphosphonates have now become a part of standard therapy to treat and prevent skeletal-related events (SRE), it could inhibit osteoclast-mediated bone resorption and demonstrate antitumor activity in preclinical models. Bisphosphonates are the most effective agent for treating and (or) preventing complications of bone metastasis, reducing the incidence of skeletal-related events, and improving quality of life in patients with bone metastasis. |
| Authors | Peng Liang
(Affiliation: Department of Orthopaedics, the Gansu Cancer Hospital, Lanzhou 730050, Gansu, China. liangplz0801 at hotmail.com)
|
| Journal | Zhongguo gu shang = China journal of orthopaedics and traumatology
(Zhongguo Gu Shang)
Vol. 21
Issue 6
Pg. 480-2
(Jun 2008)
ISSN: 1003-0034 China |
| PMID | 19108448
(Publication Type: English Abstract, Journal Article, Review)
|
| Chemical References |
|
| Topics |
- Apoptosis
(drug effects)
- Bone Neoplasms
(drug therapy, pathology, secondary)
- Diphosphonates
(adverse effects, pharmacology, therapeutic use)
- Humans
- Neoplasm Invasiveness
|
